National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients (CARMEN)

Floralis

Status: Completed

Conditions: Venous Thromboembolism; Neoplasms

Treatments: Procedure: VTE treatment in cancer patient description

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01362933

Version N°2.0 du 21/03/2011

Details and patient eligibility

About

Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.

Enrollment: 502 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months. VTE can be symptomatic or asymptomatic, can be located close to a central line, and of any type (DVT, PE, SVT)

Exclusion criteria

• Patient already included in a trial studying antithrombotic therapy
• Patient refusing the study
• Patient under 18 and/or not competent to give informed consent

Trial design

502 participants in 1 patient group

VTE treatment in cancer patient

Description:

All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.

Treatment:

Procedure: VTE treatment in cancer patient description